Hanall Biopharma Co.,Ltd Announces Consolidated Earnings Results for the Second Quarter and Six Months of 2021
July 29, 2021 at 04:14 pm IST
Share
Hanall Biopharma Co.,Ltd announced consolidated earnings results for the second quarter and six months of 2021. For the quarter, the company reported sales of KRW 23.4 billion compared to KRW 22.6 billion a year ago. Operating profit was KRW 1.6 billion compared to KRW 1.6 billion a year ago. Net income was KRW 3.3 billion compared to KRW 5.9 billion a year ago.
For the six months, the company reported sales of KRW 51.2 billion compared to KRW 44.7 billion a year ago. Operating profit was KRW 7.0 billion compared to KRW 4.5 billion a year ago. Net income was KRW 7.8 billion compared to KRW 9.8 billion a year ago.
Hanall Biopharma Co Ltd is a Korea-based company principally engaged in the manufacture and distribution of synthetic pharmaceuticals and biopharmaceuticals. The Company mainly manufactures and sells pharmaceutical products including antidiabetic drugs, skin drugs, muscle relaxants, hepatitis drugs, digestion drugs, anti-cardiovascular drugs, neurologic drugs, interferons, antiviral drugs, antibiotics, antihistamine, anti-inflammatory drugs, and others. The Company also engages in the leasing of real estates. The Company distributes its products in domestic and overseas markets.
HANALL BIOPHARMA CO., LTD. 
